文献速递妇科

择期妇科手术女性阿片类药物处方实践:基于人群的回顾性队列研究

Opioid Prescribing Practices for Women Undergoing Elective Gynecologic Surgery.
PubMed 文献 · J Minim Invasive Gynecol · 2021-01-24

该研究基于加拿大安大略省行政数据,纳入2013至2018年接受良性指征择期妇科手术的阿片类未暴露成年女性132 506例,描述围术期阿片类药物处方实践并分析相关风险因素。结果显示21.0%患者存在围术期阿片类药物使用,比例从2013年21.8%显著降至2018年18.5%(p <.001);围术期使用是新发持续使用的独立风险因素(调整相对风险1.40;95%CI 1.13-1.72),每65例处方者中1例发生新发持续使用。

要点

  • 约1/5接受妇科手术的女性出现围术期阿片类药物新暴露。
  • 围术期阿片使用使持续使用风险增加40%(aRR 1.40;95%CI 1.13-1.72)。
  • 每65例术后阿片处方者中1例发生新发持续使用。

核心结论

  • 接受妇科手术的女性中约五分之一出现围术期阿片类药物新暴露。
  • 每65例术后填写阿片类药物处方者中1例发生新发持续使用。
  • 围术期阿片使用是新发持续使用的独立风险因素。

研究设计与样本

  • 回顾性、基于人群的队列研究,使用加拿大单支付方省级医疗系统关联行政数据。
  • 纳入2013至2018年接受良性指征择期妇科手术的阿片类未暴露成年女性,共132 506例。
  • 采用多变量对数线性回归调整临床和人口学数据。

主要发现

  • 74.3%患者接受小型妇科手术。
  • 27 763例(21.0%)存在围术期阿片使用,比例从2013年21.8%显著降至2018年18.5%(p <.001)。
  • 围术期阿片使用增加的风险因素包括年轻年龄、较高收入五分位、城市居民、不孕症、子宫内膜异位症或附件包块诊断。
  • 围术期阿片使用是新发持续使用的独立风险因素(调整相对风险1.40;95%CI 1.13-1.72)。
  • 新发持续使用最高风险因素为填写高剂量阿片处方(调整相对风险第5五分位OME 2.33;95%CI 1.83-2.96)。

关键数值与推荐

  • 围术期阿片使用定义为术前30天至术后14天内≥1次阿片处方。
  • 新发持续阿片使用定义为术后91至180天填写≥1次阿片处方。

临床怎么用

  • 妇科手术围术期应审慎评估阿片类药物处方指征,关注高风险人群。
  • 对年轻、高收入、城市居民及不孕症、子宫内膜异位症或附件包块患者加强阿片使用监测。
  • 避免高剂量阿片处方以降低新发持续使用风险。

局限性

  • 回顾性行政数据研究可能存在未测量混杂。
  • 仅反映加拿大安大略省单一支付方系统人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: To describe the opioid prescribing practices in opioid-naive women undergoing elective gynecologic surgery for benign indications and identify risk factors associated with increased perioperative opioid use. We also explored factors associated with new persistent opioid use in women with perioperative opioid use. DESIGN: Retrospective, population-based cohort study. SETTING: We used linked administrative data from a government-administered single-payer provincial healthcare system in Canada. This study was undertaken at ICES, a not-for-profit research institute in Ontario, Canada. PATIENTS: We followed opioid-naive adult women who underwent benign elective gynecologic surgery between 2013 and 2018. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The primary outcome was perioperative opioid use defined as ≥1 opioid prescription from 30 days before to 14 days after surgery. New persistent opioid use after gynecologic surgery was defined as having filled 1 or more opioid prescriptions between 91 days and 180 days postoperatively. Multivariable log-linear regression analyses were employed to adjust for clinical and demographic data. Of the 132 506 patients included in our cohort, most (74.3%) underwent minor gynecologic procedures. Perioperative opioid use was documented in 27 763 (21.0%) patients, and there was a significant decreasing trend (p <.001) in the proportion of patients with perioperative opioid use from 21.8% in 2013 to 18.5% in 2018. Factors associated with increased perioperative opioid use included younger age; higher income quintile; urban dwellers; and diagnosis of infertility, endometriosis, or adnexal mass. Perioperative opioid use was an independent risk factor for persistent use (adjusted relative risk 1.40; 95% confidence interval, 1.13-1.72) and for every 65 patients prescribed opioids associated with gynecologic surgery, one developed new persistent opioid use. The highest risk factor for developing persistent use was filling a high-dose opioid prescription (adjusted relative risk5th quintileOME 2.33; 95% confidence interval, 1.83-2.96). CONCLUSION: One in 5 women who undergo a gynecologic procedure has a new exposure to opioids. For every 65 patients who fill an opioid prescription after their gynecologic surgery, one will experience prolonged opioid use.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Chan WV, Le B, Lam M, et al. Opioid Prescribing Practices for Women Undergoing Elective Gynecologic Surgery. J Minim Invasive Gynecol. 2021. PMID: 33503472. doi:10.1016/j.jmig.2021.01.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。